DCM
RIGL icon

Dupont Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Dupont Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,118
Closed -$183K – 1734
2022
Q1 		$183K Sell
6,118
-541
-8% -$14.6K 0.01% 1080
2021
Q4 		$176K Sell
6,659
-10,064
-60% -$304K 0.01% 1161
2021
Q3 		$607K Buy
16,723
+3,251
+24% +$128K 0.02% 786
2021
Q2 		$585K Hold
13,472
– – 0.01% 892
2021
Q1 		$461K Sell
13,472
-2,763
-17% -$109K 0.01% 983
2020
Q4 		$568K Sell
16,235
-1,212
-7% -$35.1K 0.01% 796
2020
Q3 		$419K Buy
17,447
+5,222
+43% +$128K 0.01% 835
2020
Q2 		$224K Buy
+12,225
New +$220K ﹤0.01% 1087

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dupont Capital Management's RIGL Position: Q2 2022 in Review

Dupont Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 6,118 shares — an estimated $183K sold.

Dupont Capital Management first reported a position in RIGL in Q2 2020 and held it in 8 quarters. The position peaked at $607K in Q3 2021. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Dupont Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Dupont Capital Management sold 6,118 Rigel Pharmaceuticals shares in Q2 2022, an estimated $183K.
  • Dupont Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2020 and held it in 8 quarters.
  • Dupont Capital Management's Rigel Pharmaceuticals position peaked at $607K in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Dupont Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.